Peptidomimetic Drug Screening Service

As one of the world's leading biotechnology companies, CD BioSciences has state-of-the-art equipment and experienced staff. Our high-throughput peptidomimetic development platform can provide drug screening services for a variety of disease mechanisms according to customers' project needs, and meet the needs of global customers in drug discovery and other related fields.

Introduction to Drug Screening

• Drug screening is a step in the modern drug development process to test and obtain specific physiologically active compounds. It refers to the process of selecting compounds with higher activity from a large number of compounds or new compounds through standardized experimental methods.
• During the screening process of drug lead compounds, 40%-60% of the lead compounds are eliminated in the subsequent validation links (drug absorption, distribution, metabolism, secretion and toxicity testing). 72% of drug development costs are wasted on: increasing clinical costs, unpredictable regulatory environments in the body, and drug side effects. Therefore, the selection of high-quality lead compounds is a crucial process in drug screening.
• CD BioSciences peptidomimetic drug screening adopts a cell-based phenotype screening method to evaluate the biological activity, pharmacological effect and medicinal value of peptidomimetic molecules that may be used as drugs.

Our Services

CD BioSciences provides peptidomimetic drug screening services by disease classification.

Our Service Processes

CD BioSciences is dedicated to providing a variety of services for peptidomimetic drug screening. The types of diseases we target are not limited to the above-mentioned ones, and we can provide customized services according to the client's project direction. As long as you are interested in any aspect of peptidomimetic drugs, please contact us for the best solution.

Related Services